Earnings call
Advanced Enzyme Technologies Q4 FY25 earnings call: Advanced Enzyme Technologies Limited expects gross contribution of 76% to 77% to be maintainable as of now
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company expects gross contribution of 76% to 77% to be maintainable as of now. The company completed installation and commissioning of an additional 350-kilowatt solar power plant, raising its total clean energy capacity to 510 kilowatts. The company reported top line of INR1,672 million in the quarter ended March 31, 2025, up 6% year on year and down 1% sequentially. The company filed 3 patent applications related to sugar technologies.
The numbers management gave
Results
- The company reported top line of INR1,672 million in the quarter ended March 31, 2025, up 6% year on year and down 1% sequentially.
Show source
Now, as far as the quarterly performance is concerned, we achieved a top line of INR1,672 million, growth of 6% on a year-on-year basis and degrowth of 1% on a sequential basis in quarter 4.
- The company reported EBITDA of INR456 million and EBITDA margin of 27% and PAT margin of 16% in the quarter ended March 31, 2025; the lower EBITDA margin was due to a change in product mix and true-up of inventory valuations at year-end.
Show source
EBITDA margin stood at 27% and PAT margin stood at 16% during the quarter 4.
- Total revenue grew 2% to INR6,369 million in the year ended March 31, 2025.
Show source
During financial year '25, the total revenue grew by 2% to INR6,369 million.
- The company reported EBITDA of INR1,944 million, equal to 31% of sales, and net profit of INR1,340 million in the year ended March 31, 2025.
Show source
EBITDA at INR1,944 million is 31% of sales.
- Human Nutrition contributed 62% of Advanced Enzyme Technologies Limited's revenue in the quarter ended March 31, 2025, growing 1% year on year and sequentially; for the year ended March 31, 2025, revenue declined by INR132 million, about 3%, mainly due to lower domestic-market revenue while the U.S.A. and other international markets grew, and the segment constituted about 64% of revenue.
Show source
Annually, on a full year basis, revenues went down by INR132 million, about 3%, mainly due to lower revenue from domestic markets, while U.S.A. and other international markets witnessed growth.
- Animal Nutrition contributed 12% of Advanced Enzyme Technologies Limited's revenue in the quarter ended March 31, 2025.
Show source
Our Animal Nutrition business contributed 12% to the revenue in quarter 4.
Show 17 more statements
Results
- Bio-Processing contributed 17% of Advanced Enzyme Technologies Limited's revenue in the quarter ended March 31, 2025, growing around 8% year on year and declining 13% sequentially.
Show source
This segment grew during the quarter by around 8% on year-on-year basis, while degrew by 13% on sequential basis.
- Food business grew 4% to INR809 million, about 13% of total revenue, and its non-food business grew 12% to INR208 million, 3% of total revenue, in the year ended March 31, 2025.
Show source
Annually, our food business grew by 4% to INR809 million, constituting about 13% of the total revenue, while non-food business grew by 12% to INR208 million.
- Consolidated revenue decreased INR19 million, or 1%, from INR1,691 million to INR1,672 million sequentially in the quarter ended March 31, 2025.
Show source
The revenue has decreased by INR19 million, by 1 percent point from INR1,691 million to INR1,672 million.
- Consolidated EBITDA margin was 27% versus 31%, profit before tax was 26% versus 31%, and PAT was INR267 million versus INR389 million in the quarter ended March 31, 2025, compared with the corresponding previous quarter.
Show source
The EBITDA margin stood at 27% as compared to 31% in the corresponding previous quarter; profit before tax at 26% as compared to 31%; and PAT during the quarter was INR267 million as compared to INR389 million.
- Consolidated revenue was INR1,672 million, up 6% from INR1,578 million year on year in the quarter ended March 31, 2025.
Show source
On year-on-year basis, the revenue is at INR1,672 million as compared to INR1,578 million, an increase of 6%.
- JC Biotech's revenue was INR600 million, EBITDA was INR70 million and PAT was INR12 million in FY '25, compared with INR626 million, INR77 million and INR18 million, respectively, in FY '24.
Show source
JC Biotech's revenue stood at INR600 million during FY '25 as compared to INR626 in FY '24.
- Evoxx's loss was about INR39 million in FY '25, up from INR21 million in FY '24.
Show source
And the loss at Evoxx is about INR39 million, up as compared to INR21 million in FY '24.
- SciTech's revenue was INR542 million in FY '25 compared with INR418 million in FY '24, a growth of 30%.
Show source
Revenue is at INR542 million as compared to INR418 million in FY '24, 30% of growth.
- Consolidated R&D spend, without intercompany elimination, was about 5.32% in Q4 compared with 4.7% in Q4 of FY '24.
Show source
On a consolidated basis, R&D spend is about 5.32% in Q4 and 4.7% in Q4 of FY '24.
- Consolidated R&D spending with elimination was about 4.4% in Q4 compared with 3.5% in Q4 of FY '24.
Show source
And on a consolidated basis, R&D spending with elimination is about 4.4% as compared to 3.5% in Q4 of FY '24.
- Consolidated R&D spend was 5.3% in FY '25 compared with 4.53% in FY '24.
Show source
On consolidated basis, R&D spend for FY '25 is at 5.3% as compared to 4.53% in FY '24.
- The company generated about 315,000 units from the panels over the last year.
Show source
That is somewhere around like -- for the last year, we generated about 315,000 units, somewhere around that.
- The panels provided 10% of Advanced Enzyme Technologies Limited's total consumption at Sinnar as of the call.
Show source
But that is almost like 5% to 10% of our total -- 10% of our total consumption as of now, what we use at Sinnar.
- The company reported Human Nutrition revenue of INR1,764 million in India and INR2,289 million in international business for FY '25.
Show source
It's INR1,764 million.
- Gross contribution was 77% in FY '24 and 76% in FY '25; the lower figure reflected product mix, as sales of some products that might fetch very good margins were lower than in the previous quarter.
Show source
So when you look at the yearly -- annual numbers of FY '25 and FY '24, so only you see, the 77% is the gross contribution for FY '24.
- EBITDA margin was about 32% in FY '24 and about 31% in FY '25.
Show source
And EBITDA margin was about 32% in FY '24.
- Industrial Bio-Processing segment contributed about 19% to total revenue from operations in Q3 FY25.
Show source
Mukund Kabra: 19%.
What it expects ahead
What management expects
- The company expects gross contribution of 76% to 77% to be maintainable as of now.
Show source
Beni Rauka: I think that's what, 76%, 77% is the kind of gross contribution, which we shall be in a position to maintain as of now.
- The company sees pressure and challenges continuing in serratiopeptidase and may see a further 2% to 5% fall in revenue in this area; the company may bring out other products to provide growth.
Show source
We may see that there might be another 2%, 3% to 5% fall on the revenue on this particular area.
- The company expects its Specialized Manufacturing business to grow more than 20% in the coming year, supported by created capacities and the plants operating full-fledged in FY '25 after a fire impacted manufacturing in FY '24.
Show source
I think if not 30%, at least this business is going to grow more than 20% in the coming year as well.
- The company considers an EBITDA margin of 30%, 31% sustainable when preparing its business model for a couple of years.
Show source
So 30%, 31% of EBITDA margin is something like is sustainable in that sense.
- The company sees growth of around a mid-double-digit number for this year and a very positive year ahead.
Show source
But when we do this and when we look forward for this year, we see a good growth at somewhere around like mid-double-digit number.
- The company expects a turnaround at Evoxx this year.
Show source
Definitely, this year, we will see turnaround.
What it is building and selling
Projects and capacity
- The company completed installation and commissioning of an additional 350-kilowatt solar power plant, raising its total clean energy capacity to 510 kilowatts.
Show source
The company has successfully completed the installation and commissioning of an additional 350-kilowatt solar power plant, raising its total clean energy capacity to 510 kilowatts.
- The company installed panels with a capacity of 510 kilowatts on the plant itself.
Show source
Right now, what we put up is like a 510-kilowatt capacity of the panels on the plant itself.
- The company established Starya Labs, a separate independent laboratory under its U.S. subsidiary for testing enzyme and probiotic products.
Show source
The company has established a separate independent laboratory named Starya Labs under its U.S. subsidiary for testing enzyme and probiotic products.
- The company is exploring options for solar, including forming a joint venture company and buying it.
Show source
We are looking for some other options as well on the solar, there are certain options like making a joint venture company and buying it.
- The company expects to finish construction of the R&D center by December of this year, with some portion expected to start in the last quarter of this year.
Show source
Mukund Kabra: So we expect to finish the construction work by the December of this year.
Segments
- The company filed 3 patent applications related to sugar technologies.
Show source
Furthermore, the company has filed 3 patent applications related to innovative sugar Page 2 of 13 Advanced Enzyme Technologies Limited May 14, 2025 management technologies.
Show 1 more statement
Segments
- U.S. facility is more focused on blending or the final product side than fermentation, and most raw material needed for the U.S. goes from India.
Show source
So most of the raw material, what is needed for U.S. goes from India.
Risks, rules and outside factors
Outside factors
- The company faces a 10% duty and, based on last year, might have an impact of about $400,000; business that may come because of instability could potentially offset this impact and support higher growth, depending on how matters develop.
Show source
So right now, there is a 10% duty, which if we just go by the last year, probably, we might have an impact of about $400,000.
Rules and policy
- The company filed 2 GRAS Dossiers with the U.S. FDA supporting food processing enzyme use in baking, brewing, starch processing and oligosaccharide production.
Show source
In the United States, 2 GRAS Dossiers have been filed with the U.S. FDA, supporting the use of food processing enzymes in baking, brewing, starch processing and oligosaccharide production.
- The company filed a food enzyme dossier with the European Food Safety Authority for approval; the enzyme is intended for baking and the production of refined edible fats and oils.
Show source
The compa ny has filed a food enzyme dossier to the European Food Safety Authority for approval.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Umang Shah: Sir, first question was pertaining to the biggest product that we sell, which is serratiopeptidase. Sir, in Q4, how has the competitive intensity reduced? And how do we think about it in FY '26? And second is, if you could repeat how much did it contribute to the total revenues for FY '25 that would be great ?
Answer, mukund kabra
Mukund Kabra: 19%. But we see that there will be some challenge into this area, particular area. We see that it will have the pressure going forward as well. And as a policy, we will come out with some other products, which will give us the growth. We may see that there might be another 2%, 3% to 5% fall on the revenue on this particular area.
Question
Umang Shah: Okay. And sir, one more question was, you had launched products in weight management, sugar management and protein digestion last year. What percentage of revenues do they bring in right now?
Answer, mukund kabra
Mukund Kabra: Umang ji, I don't know the exact percentage, but still we didn't get those kind of volumes which were expected, but a lot of growth from the U.S. is coming from other segments and other areas as of now. We are still working on those areas, but the traction what we expected didn't come out last year.
Question
Umang Shah: Sure, sir. Sir, and one question was that 2, 3 quarters back, Raukaji mentioned that the peak margins that this business can go to is 32%, 33%. Considering our revenue growth, what you were envisaging at that time and now what we are looking at, do you still think the company can have the margin potential over next 3 to 5 years? Or do you want to have a rethink on the same?
Answer, mukund kabra
Mukund Kabra: What I can say is right now, we expect the same margin of this year for the coming year. When the revenue grows, probably it may grow. But for the calculations purpose, we are going with the same number of this year.
Question
Shubham Sehgal: I'll just repeat it. So we have been facing difficulties on our marketing front, be it the higher cost or the mismatch expectations. So my question is, what are we doing actively on this front? And have we found any success at all in sorting our marketing issues?
Answer, beni rauka
Beni Rauka: Okay. I think to our knowledge, as such, I think only the issue we might have mentioned is that we have to expand our marketing efforts in particularly overseas market. And that's where like we might have discussed that for a particular segment or a particular category of products when Page 7 of 13 Advanced Enzyme Technologies Limited May 14, 2025 we talk about animal feed business, how do we really expand our marketing reach to overseas market where a lot of issues are there for the registration of the products, for having a distributor. And for the food business as well, we might have discussed this thing. But I don't remember that there is any kind of mismatch and any kind of issues we are facing in that sense. So the only challenges were like how to really ramp up getting your product registered with European food safety authorities, how do you register your products with various countries? And even there are some countries where when you want to import, so the local distributor, they have to register their products.
Answer, beni rauka
So those were kind of challenges, which, of course, in the last couple of years, we have ramped up and we have really got some kind of breakthroughs, and we have used a lot of resources to have that kind of a thing in place. But yes, a lot more is to be done, and it will take a couple of years to have that kind of a distribution network.
Question
Shubham Sehgal: Yes, the solar plant.
Answer, mukund kabra
Mukund Kabra: The solar plant. No, this is not a solar plant what we put up. Right now, what we put up is like a 510-kilowatt capacity of the panels on the plant itself. That is somewhere around like -- for the last year, we generated about 315,000 units, somewhere around that. But that is almost like 5% to 10% of our total -- 10% of our total consumption as of now, what we use at Sinnar. We are looking for some other options as well on the solar, there are certain options like making a joint venture company and buying it. But we are exploring all of that.
Answer, mukund kabra
And probably we will look into this year to establish that as well.
Question
Shubham Sehgal: Okay. Just my last question on our Specialized Manufacturing segment. So can we expect this segment to grow like at a 30% rate sustainably? And what are the factors currently driving this growth?
Answer, beni rauka
Beni Rauka: Yes. I think if not 30%, at least this business is going to grow more than 20% in the coming year as well. And the factors is like the capacities have been created. In FY '24, there was a challenge. I think we have mentioned earlier, there was a fire in that plant. So because of that, the manufacturing has, to some extent, impacted. So FY '25, full-fledged like the plants were in operation.
Answer, beni rauka
And we also added some capacity in FY '25. Page 8 of 13 Advanced Enzyme Technologies Limited May 14, 2025 So now, we are getting a lot of orders and inquiries, and we are signing a lot of contracts. So that helps us to have a better visibility of the revenue in FY '26. And we -- again, we are also working on expanding more capacity of this particular plant going forward.
Question
Shubham Sehgal: So are we seeing more demand traction from international markets or domestic markets or both of them?
Answer, beni rauka
Beni Rauka: So it's like both as such. But yes, this year, we could see that a lot of growth has come from the Indian market only.
Answer, beni rauka
Beni Rauka: So I mean, of course, the U.S. has a better margin as whatever manufacturing -- core manufacturing is happening in India and U.S. is doing some kind of customized formulation. So they do fetch a better margin in that sense because their approach is completely -- one is solution- based approach. And over a period of time, they have created their own branding. So they fetch better margin as compared to India business. And apart from that, we have a couple of subsidiaries. Now these subsidiaries are like -- again, 2, 3 subsidiaries are 100% subsidiaries. So they are into a different business.
Answer, beni rauka
Their margins are different. They have a -- like if I talk about Bio-Processing non-food, so non-food business has kind of low margins. Food business is slightly better. Animal feed has a different kind of a margin. So U.S. has, of course, a better margin in that sense. So, as the U.S. business will grow, definitely, we could see better margin. But then, of course, now going forward, as a lot of challenges are there because of the tariff issues, so we have to see that -- there may be some kind of a competition which comes when you have this kind of margins in the business.
Answer, beni rauka
So those factors definitely we'll always take into account. And that's the reason we are saying that going forward, we shall be taking up only when you prepare your business model for a couple of years. So 30%, 31% of EBITDA margin is something like is sustainable in that sense.
Question
Shreyans Gathani: Got it. So, on the U.S. market, so you mentioned that last year, the products that we launched did not see a lot of traction as you expected. So are there any other products that we are launching? Or like is that picking up now? Or how do you see them playing out this year?
Answer, mukund kabra
Mukund Kabra: So this year, probably we will see it better growth-wise or otherwise. It's a little bit slower than what our expectations were in the beginning. But at the same time, we are working on some Page 9 of 13 Advanced Enzyme Technologies Limited May 14, 2025 other areas like the -- and which was the existing business as well, which has grown much better. And this year also, we see that most of the growth in the U.S. has to come -- also has to come from the existing businesses right now.
Question
Shreyans Gathani: Okay. So the newer introductions are not going to contribute significantly?
Answer, mukund kabra
Mukund Kabra: They will contribute, but they will take some more time than what we initially anticipated.
Question
Shreyans Gathani: Got it. So could you just give some idea on like why we are -- like it's not picking up as fast? Is that like slower customer adoption or there's competition more than we thought? Or could you just give some idea on why...
Answer, mukund kabra
Mukund Kabra: It was in anticipation. The earlier expectations were based on the MLM model, and the company with whom we were working was those were all their projections. And based on that, we come out with those projections. But then slowly, slowly, we slowed down on the MLM side, and then we are working with some other more people to expand this market. So it's a process, right? So the time consumption is a bit more right now.
Show 16 more questions
Question
Shreyans Gathani: Got it. My next question is on the R&D center update. Could you just share where we are with that? And I think we expect the Phase 1 to be started this year, if that's on track or not?
Answer, mukund kabra
Mukund Kabra: So we expect to finish the construction work by the December of this year. And some portion will start in the last quarter of this year, particularly. And so, I mean, it's a 5-floor building. The last slab is in process right now, and then all the other civil work has to be done. But it is on track right now.
Question
Shreyans Gathani: Okay. So the WELLFA business is going to go there.
Answer, mukund kabra
Mukund Kabra: Yes, so that more focus can come into that. We feel that now it's time to put some focus on that particular area as well.
Question
Shreyans Gathani: Got it. Understood. And just last question on the Evoxx business. There was like an order a quarter or 2 ago. Is there any update on that? And is there any other opportunities that we are looking on that front?
Answer, mukund kabra
Mukund Kabra: Yes. So, that order has already materialized. I guess, I already confirmed that, right, whatever we were talking on that. And we are working on that. In similar areas, we are still talking with a couple of more people. But as of now, it's in the process. Page 10 of 13 Advanced Enzyme Technologies Limited May 14, 2025 Shreyans Gathani: Got it.
Question
Shreyans Gathani: Okay. So we should see the losses reducing from Evoxx this year?
Answer, beni rauka
Beni Rauka: Definitely. Definitely, this year, we will see turnaround.
Question
Ambuj Chaudhary: Yes. So globally, it's a trend that every other major chemical players and R&D companies are incorporating artificial intelligence to speed up and streamline their R&D processes like time to market, molecule discovery and all sort of things. So is our company doing -- implementing artificial intelligence in any way in R&D?
Answer, mukund kabra
Mukund Kabra: Yes, we are exploring. This year, that is one of the tasks for us to go forward. We are working on that. Probably this year, we will implement some of them.
Question
Ambuj Chaudhary: Okay. And the next question is, what would be the guidelines for this financial year? What would you expect like any surprises in any way possible from any geographic market or any product?
Answer, mukund kabra
Mukund Kabra: There can be a lot of surprises. But what we expect is, as I already said, maybe like a mid-double- digit growth as of now. We might see better as well, depending on how the global things turn out. And also, we are looking into the -- some kind of intermediate kind of a business. And if that works out, clearly, there can be -- the top line can be much higher.
Question
Umang Shah: Sir, in the calls, you break out the Human Nutrition revenues between India and international. Could you please do this?
Answer, beni rauka
Beni Rauka: Yes, So Umang, I'm giving you for FY '25. It's INR1,764 million. And international business is INR2,289 million.
Question
Umang Shah: Okay. Sure. Great, sir. And sir, one question was, biocatalyst business, we have been in conversation with pharma companies for quite some time. So what are the challenges here for them to adopt this solution that we have?
Answer, mukund kabra
Mukund Kabra: So yes, there were some challenges, like as I already talked on the -- earlier as well, for one of the molecules, the -- for example, the lead cost has gone up and all of those sort of things were there -- lithium, not lead. But then, we come out with some other ways for this year, particularly. And this year, probably, we should see a good growth in that particular area.
Question
Umang Shah: Right, sir. And sir, you mentioned that the India pharma business will continue to be stressed in next year also. So in that context, sir, some other segment will have to have a higher growth, Page 11 of 13 Advanced Enzyme Technologies Limited May 14, 2025 10% to 15% growth for us to actually grow at, say, high-single digit in the next 1 to 3 years. So which segments are you more optimistic about?
Answer, mukund kabra
Mukund Kabra: The biocatalyst area right now.
Question
Umang Shah: Okay, sir. And sir, animal feed, industrial processing, any color on that?
Answer, mukund kabra
Mukund Kabra: Animal feed will do also very good this year. But the problem is a low base. So even though whenever we talk it about good, when we talk about overall growth, its contribution is on the lower side when we -- even like -- so animal feed should also do good. Food will be, I would say, normal for this year, particularly. This year, major growth will start coming from the HN only.
Question
Umang Shah: And sir, with the largest product that we sell, do we think that this is the new normal in terms of margins and sales growth and the competition is here to stay? Or do we think that we will revert back to our own profitability and sales composition once thes e temporary issues are done away with?
Answer, mukund kabra
Mukund Kabra: I think it's a game we can sustain, right? So it will take some more time, maybe 2, 3 years, and then we'll see how that pans out. There will be some quarters when we will see the good growth. Some quart ers, we will be the normal ones, depending on the situation in the market. But for the calculation purposes, we are going with this as a normal right now.
Question
Umang Shah: Right, sir. And sir, what would be the discount that the competitors offer to the product that we sell, if you are able to talk about it?
Answer, mukund kabra
Mukund Kabra: There will be the erosion on that front, somewhere around 5% to 7%, particularly as of now. That is what we are taking into the consideration for the next year, particularly.
Question
Umang Shah: Sure, sir. And the demand growth will not be significant here. So you are actually looking at a volume decline more or less?
Answer, mukund kabra
Mukund Kabra: No, we will see the volume may grow, but actual realization may be at the same level.
Question
Shubham Sehgal: Yes. Just a follow-up on a previous question, so like about the gross margins itself. So in the last 5, 10 years, if we see our quarterly gross margins, so like never we have witnessed like su ch low gross margins of 72%. So I mean, I heard that you said that we did some inventory revaluation. But still this kind of margins, we have not seen yet. So like could you just elaborate on that? Is it possible we price our products lower to drive growth or something like that? Because these low gross margins, we haven't seen. And also from next quarter, what gross margins can we expect? Page 12 of 13 Advanced Enzyme Technologies Limited May 14, 2025 Mukund Kabra: See, on the raw mate
Answer, beni rauka
Beni Rauka: Shubham, I think you are looking at quarter -- so you should look at the yearly numbers, annual numbers. And I have already explained then some true-up has been done. It's not like a true-up is having a very substantial impact on this overall basis. And here, the question was like the product mix, which we have mentioned to you, some of the products which might be fetching very good margins. If the sale of those products during the quarter is low, is lower than previous quarter, then you see the overall gross margin and EBITDA margin that gets impacted. So when you look at the yearly -- annual numbers of FY '25 and FY '24, so only you see, the 77% is the gross contribution for FY '24. And FY '25, it is 76%.
Answer, beni rauka
And EBITDA margin was about 32% in FY '24. And this year, we are having about 31%. So only the quarter-to-quarter comparison is something which is...
Question
Shubham Sehgal: So, on a yearly basis, then what kind of gross margins can we expect going forward?
Answer, beni rauka
Beni Rauka: I think we are -- I already mentioned we should -- we are maintaining the kind of EBITDA margin and gross margin in the same level.
Question
Shubham Sehgal: Okay. So in the range of 76% to 77%, then?
Answer, ronak saraf
Ronak Saraf: Thank you, everyone, for taking your valuable time for attending our earnings conference call. We will keep you posted for any further updates. I request you all to kindly send in your questions that may remain unanswered. An audio recording and the transcript of this call will be uploaded on our website in due course. Looking forward to host you all in the next quarter. Till then, stay healthy, stay safe.
Questions about this call
- When was the Advanced Enzyme Technologies Q4 FY25 earnings call transcript filed?
- Advanced Enzyme Technologies filed the transcript with the exchange on 19 May 2025. This page is built from that transcript.
- What does this page list?
- 39 statements from the transcript across 6 topics, 32 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 26 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.